SNSE

Sensei Biotherapeutics, Inc.

0.70 USD
+0.10 (+15.82%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Sensei Biotherapeutics, Inc. stock is down -53.33% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 June’s closed higher than May. 100% of analysts rate it a buy.

About Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics, Inc. engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer.

  • Citigroup
    Mon Jun 3, 15:11
    buy
    confirm
  • HC Wainwright & Co.
    Fri May 24, 12:37
    buy
    confirm
  • Stephens & Co.
    Fri May 24, 11:44
    buy
    confirm